We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Fingolimod

News List

A Blockbuster to Arrive in the Multiple Sclerosis Area of China! PharmaSources/Caicai
July 24, 2019
Novartis’ Fingolimod with Annual Sales Exceeding USD3 Billion to be Marketed Soon in China
Significant Number of Referred Patients Misdiagnosed With MS drugs
April 28, 2019
Among pediatric patients with relapsing multiple sclerosis, fingolimod is associated with a lower rate of relapse but a higher rate of serious adverse events than interferon beta-1a, according to a study published in the Sept.
Fingolimod Cuts Multiple Sclerosis Relapses in Pediatric Patients drugs
September 13, 2018
Among pediatric patients with relapsing multiple sclerosis, fingolimod is associated with a lower rate of relapse but a higher rate of serious adverse events than interferon beta-1a, according to a study published in the Sept. 13 issue of the New England